Literature DB >> 2931222

In vitro studies on the mechanism of increased serum IgM levels in primary biliary cirrhosis.

K T Nouri-Aria, J E Hegarty, J Neuberger, A L Eddleston, R Williams.   

Abstract

To evaluate the mechanisms underlying the increase in serum IgM in primary biliary cirrhosis (PBC) studies were designed to examine IgM production in vitro and to assess the relative contribution of intrinsic B cell activity and immunoregulatory T cell balance to IgM synthesis. The number of peripheral blood lymphocytes (PBL) producing IgM (spontaneous and pokeweed mitogen (PWM) stimulated) at the end of a seven day culture period was similar in PBC patients and control subjects while the amount of IgM synthesized (spontaneous and PWM stimulated) during this period was significantly greater in the patient group, implying that the amount of IgM produced per B cell was increased in PBC. Co-culture of autologous and allogeneic T and B lymphocytes and irradiation of T lymphocytes from patients and normal subjects clearly implicated abnormal suppressor T cell function, rather than autonomous B cell hyperactivity, as the cause of the increased IgM synthesis. Direct studies of T cell function indicated that although concanavalin A (Con A) activated suppressor cells inhibited proliferation of IgM producing B cells in the majority of PBC patients, they were unable to inhibit IgM synthesis. The demonstration of a disparity between IgM synthesis and the proliferation of IgM-producing B cells, together with the observation that the abnormality of T cell function is largely confined to the control of IgM secretion, is consistent with the presence of at least two different suppressor subpopulations regulating IgM production. In PBC the main suppressor cell abnormality seems to affect regulation of IgM secretion rather than B cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2931222      PMCID: PMC1577296     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  The E-rosette assay: a cautionary note.

Authors:  E W Gelfand; A Shore; B Green; M T Lin; H M Dosch
Journal:  Clin Immunol Immunopathol       Date:  1979-01

2.  The presentation and diagnosis of 100 patients with primary biliary cirrhosis.

Authors:  S Sherlock; P J Scheuer
Journal:  N Engl J Med       Date:  1973-09-27       Impact factor: 91.245

Review 3.  Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity.

Authors:  A C Allison; A M Denman; R D Barnes
Journal:  Lancet       Date:  1971-07-17       Impact factor: 79.321

4.  Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications.

Authors:  D Doniach; I M Roitt; J G Walker; S Sherlock
Journal:  Clin Exp Immunol       Date:  1966-07       Impact factor: 4.330

5.  Immune response to phi X 174 in man. 5. Primary and secondary antibody production in primary biliary cirrhosis.

Authors:  H C Thomas; R Holden; J V Jones; D B Peacock
Journal:  Gut       Date:  1976-11       Impact factor: 23.059

6.  Circulating immune complexes and complement activation in primary biliary cirrhosis.

Authors:  J R Wands; J L Dienstag; A K Bhan; E R Feller; K J Isselbacher
Journal:  N Engl J Med       Date:  1978-02-02       Impact factor: 91.245

7.  Pokeweed mitogen induced differentiation of human B cells: evaluation by a protein A haemolytic plaque assay.

Authors:  L Hammarström; A G Bird; S Britton; C I Smith
Journal:  Immunology       Date:  1979-09       Impact factor: 7.397

8.  In vitro cell-mediated cytotoxicity in primary biliary cirrhosis and chronic hepatitis. Dysfunction of spontaneous cell-mediated cytotoxicity in primary biliary cirrhosis.

Authors:  J M Vierling; D L Nelson; W Strober; D M Bundy; E A Jones
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

9.  Leukocyte migration inhibition in response to biliary antigens in primary biliary cirrhosis, sclerosing cholangitis, and other chronic liver diseases.

Authors:  I G McFarlane; B M Wojcicka; D C Tsantoulas; B C Portmann; A L Eddleston; R Williams
Journal:  Gastroenterology       Date:  1979-06       Impact factor: 22.682

10.  Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors.

Authors:  L Shou; S A Schwartz; R A Good
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

View more
  5 in total

1.  Anti-mitochondrial antibody IgG subclass distribution and affinity in primary biliary cirrhosis.

Authors:  L Zhang; A P Weetman; D R Jayne; I Turner; S J Yeaman; M F Bassendine; D B Oliveira
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

Review 2.  Primary biliary cirrhosis: new perspectives.

Authors:  W C Maddrey
Journal:  Trans Am Clin Climatol Assoc       Date:  1989

3.  Antibody responses to tetanus toxoid in patients with primary biliary cirrhosis.

Authors:  D Watmough; M A French; D R Triger
Journal:  J Clin Pathol       Date:  1987-06       Impact factor: 3.411

4.  Lymphocytes from patients with primary biliary cirrhosis spontaneously secrete high levels of IgG3 in culture.

Authors:  P Bird; J E Calvert; H Mitchison; N R Ling; M Bassendine; O F James
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

Review 5.  The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.

Authors:  Ying Sun; Weici Zhang; Baosen Li; Zhengsheng Zou; Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.